Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL504179 | 0.73 | ALDH1A1 (0.30) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL6313653 | 0.70 | — | — | |
| SCHEMBL28807495 | 0.65 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL14974789 | 0.64 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2 | |
| Urea SCHEMBL1840880 | 0.63 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL24272639 | 0.63 | OPRM1 (0.38) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL9400068 | 0.63 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL14501954 | 0.63 | OPRM1 (0.38) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL23982634 | 0.62 | HDAC1 (0.30) | — | |
| SCHEMBL516698 | 0.61 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0668782-B1 | COMBINATION OF ANTINEOPLASTIC AGENT AND ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER | UNIV TEMPLE (US) | 2001-04-11 | — | — | EP | claimed |
| EP-0668782-A1 | COMBINATION OF ANTINEOPLASTIC AGENT AND ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1995-08-30 | — | — | EP | claimed |
| WO-1994008625-A1 | COMBINATION OF ANTINEOPLASTIC AGENT AND ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1994-04-28 | — | — | WO | claimed |
| US-12605332-B2 | Transdermal delivery formulations | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2026-04-21 | — | — | US | disclosed |
| US-12478576-B2 | Transdermal delivery formulations | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4591711-A1 | COMPOSITIONS FOR BLOOD STORAGE AND TRANSFUSIONS | Albert Einstein College of Medicine (US) | 2025-07-30 | — | — | EP | disclosed |
| CN-120153255-A | Methods of predicting response to cancer treatment | 佩普托米克公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-4545068-A1 | TRANSDERMAL DELIVERY FORMULATIONS | Albert Einstein College of Medicine (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119868249-A | Transdermal delivery formulation | 阿尔伯特爱因斯坦医学院 | 2025-04-25 | — | — | CN | disclosed |
| US-20250064721-A1 | TRANSDERMAL DELIVERY FORMULATIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2025-02-27 | — | — | US | disclosed |
| US-20240390264-A1 | TRANSDERMAL DELIVERY FORMULATIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2024-11-28 | — | — | US | disclosed |
| CN-111132967-A | Cyclic olefin substituted heteroaromatic ring compound and application thereof | 和记黄埔医药（上海）有限公司 | 2020-05-08 | — | — | CN | disclosed |
| CN-105793422-B | Antisense-induced exon 2 inclusion in acid α -glucosidase | 萨罗塔治疗公司(美国) | 2020-03-03 | — | — | CN | disclosed |
| CN-103826456-B | GLI albumen in human cancer is targetted by small molecule | 加利福尼亚大学董事会 | 2017-09-19 | — | — | CN | disclosed |
| US-20170211073-A1 | ANTISENSE ANTINEOPLASTIC AGENT | Nakano, Kenji (JP) | 2017-07-27 | — | — | US | disclosed |
| EP-3168305-A1 | ANTISENSE ANTINEOPLASTIC AGENT | Nakano, Kenji (JP) | 2017-05-17 | — | — | EP | disclosed |
| WO-2009085216-A2 | COMPOSITIONS AND METHODS FOR DETECTING OR ELIMNINATING SENESCENT CELLS TO DIAGNOSE OR TREAT DISEASE | SQUICOR (US) | 2009-07-09 | — | — | WO | disclosed |
| EP-1960551-A2 | METHODS AND DEVICES FOR IDENTIFYING BIOMARKERS OF TREATMENT RESPONSE AND USE THEREOF TO PREDICT TREATMENT EFFICACY | Medical Prognosis Institute (DK) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007072225-A2 | METHODS AND DEVICES FOR IDENTIFYING BIOMARKERS OF TREATMENT RESPONSE AND USE THEREOF TO PREDICT TREATMENT EFFICACY | MEDICAL PROGNOSIS INSTITUTE (DK) | 2007-06-28 | — | — | WO | disclosed |
| EP-0668782-B1 | COMBINATION OF ANTINEOPLASTIC AGENT AND ANTISENSE OLIGONUCLEOTIDES FOR TREATMENT OF CANCER | UNIV TEMPLE (US) | 2001-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605332-B2 | Transdermal delivery formulations | NOS1, NOS2, VDR | ALDH1A1 1757/4885SMN1; SMN2 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.